Susquehanna Fundamental Investments’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-71,973	Closed	-$9.49M	–	1059
2025 Q1	$9.49M	Buy	71,973 +55,666	+341%	+$6.94M	0.13%	191
2024 Q4	$1.36M	Buy	+16,307	New	+$1.34M	0.02%	629
2024 Q2	$1.17M	Buy	+17,108	New	+$1.19M	0.03%	528

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.16B AUM 18.64% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Susquehanna Fundamental Investments's ITCI Position: Q2 2025 in Review

Susquehanna Fundamental Investments sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 71,973 shares — an estimated $9.49M sold.

Susquehanna Fundamental Investments first reported a position in ITCI in Q2 2024 and held it in 3 quarters. The position peaked at $9.49M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Susquehanna Fundamental Investments reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Susquehanna Fundamental Investments sold 71,973 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $9.49M.
Susquehanna Fundamental Investments first reported a position in Intra-Cellular Therapies Inc. in Q2 2024 and held it in 3 quarters.
Susquehanna Fundamental Investments's Intra-Cellular Therapies Inc. position peaked at $9.49M in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2025, filed 14 Aug 2025.